Redx Pharma Receives MHRA's Positive Response for Restarting its P-I/IIa RXC004 study
Shots:
- Redx is working on study including lower starting dose and enhanced safety monitoring- assessing safety and tolerability of drug in patients with advance malignancies
- Redx claims that RXC004 a porcupine inhibitor belong to WNT signalling pathway- seems to be an attractive combination companion for immune-oncology agents
- Redx will finalize the suspended protocol for dosing of patients in H1’19
Ref: Redx Pharma | Image: Apconix
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
